Health & Fitness
Health and Fitness
Health and Fitness
Thu, October 27, 2011
Wed, October 26, 2011
Abiomed to Release New Protect II Data and Economic Study Results at TCT 2011;; Over 20 Impella Presentations Included i
DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced its schedule of events at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from November 7-11, at the Moscone Center in San Francisco.
See below for the full schedule of TCT presentations and the Abiomed three-part breakfast series. All breakfast sessions will begin with breakfast from 6:30 a" 7:00 a.m. PT. The Impella presentations will begin at 7:00 a.m. for each session.
On the TCT show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #1917 and hands-on simulations of the Impella platform.
Live Case Updates
The company anticipates live cases utilizing Impella to be broadcast on Wednesday, November 9 and Thursday, November 10 from the participating live case sites in the main arena, coronary theater and structural heart theater in the Moscone Center. Further details will be disclosed the day of the scheduled cases, as patient status is relative to change.
TCT 2011 SCHEDULE OF EVENTS
TCT GENERAL SCIENTIFIC SESSION
MONDAY, NOVEMBER 7
5:45 p.m.
Left Main Bifurcation Stenting: An Advanced Operatoras Workshop
Session VIII: Case Reviews in Complex Left Main Procedures
Room 104
Moscone Center
- How Did I Treat This Complex Left Main in This Patient With Severely Depressed Left Ventricular Function?
Srihari S. Naidu, M.D.
TUESDAY, NOVEMBER 8
6:30 a" 8:00 a.m.
TCT BREAKFAST SESSION SPONSORED BY ABIOMED AND THE MEDICINES COMPANY:
Optimizing Outcomes in Complex Patients: Role of Pharmacology and Hemodynamic Support
Room 112
Moscone Center
- Understanding the Management Challenges of Intervention for the Complex Patient
- Assessing the Risk and Targeting the Pharmacologic Treatment: The Role of Direct Thrombin Inhibition
- Lessons Learned from PROTECT II: Role of Hemodynamic Support with Impella and Complex Case Review
- Q&A
Panel members / speakers:
- Neal Kleiman, M.D., Methodist DeBakey Heart & Vascular Center
- George Dangas, M.D., Mount Sinai School of Medicine
- William OaNeill, M.D., University of Miami
TCT GENERAL SCIENTIFIC SESSION
8:00 a" 10:00 a.m.
Poster Session: Hemodynamic Support in Emergent Patients
Brijeshwar Maini, M.D.
Poster TCT-470 Hall D
Moscone Center
Poster Session: Cost-Effectiveness and Clinical Outcomes of Impella
Brijeshwar Maini, M.D.
Poster TCT-484 Hall D
Moscone Center
Poster Session: Results from PROTECT II
William OaNeill, M.D.
Poster TCT-482 Hall D
Moscone Center
4:03 p.m.
Device-based Approaches for Heart Failure: Recent Developments and New Directions (non-CME)
Room 123
Moscone Center
- Session III: Left Ventricular Assist Devices
Temporary Left Ventricular Support: New Insights from PROTECT II
Jeffrey J. Popma, M.D.
WEDNESDAY, NOVEMBER 9
TCT GENERAL SCIENTIFIC SESSION
1:15 p.m.
Left Main Intervention
Room 120
Moscone Center
- Session II: Management of the Distal Left Main Bifurcation
Cases 10: Provisional vs. Prophylactic Hemodynamic Support
Brijeshwar Maini, M.D.
THURSDAY, NOVEMBER 10
6:30 a" 8:00 a.m.
ABIOMED-SPONSORED TCT BREAKFAST SESSION a" Management of Complex Patients, Expanding Your Practice: Latest Techniques, Applications, and Cost-Effectiveness Considerations
Room 130
Moscone Center
- The Emerging Field of Percutaneous Circulatory Support: How it May Change Our Practice
- Cost-Effectiveness Research for Impella
- Future Directions for Procedural Hemodynamic Support
- Percutaneous Right Heart Support with a Newly Developed Impella: First Clinical Experience
Panel members / speakers:
- George Vetrovec, M.D., Virginia Commonwealth University
- Srihari Naidu, M.D., Winthrop University Hospital
- Brijeshwar Maini, M.D., Pinnacle Health & Vascular Institute
TCT GENERAL SCIENTIFIC SESSION
9:45 a.m.
Tough Calls in the Cath Lab: Are You Up to the Challenge
Room 134
Moscone Center
- Session II: Demystifying Structural Heart Disease Hemodynamics
Is This Cardiac Assist Device Improving Hemodynamics or Not?
Srihari S. Naidu, M.D.
1:15 p.m.
Acute Infarct Angioplasty
Room 120
Moscone Center
- Impella Case Reviews
Brijeshwar Maini, M.D.
3:45 p.m.
How to Treat Theater: Coronary Artery Disease II
Coronary Theater
Moscone Center
- Multivessel Disease II
How Can PCI Outcomes in Multivessel Disease Be Improved?
Jeffrey J. Popma, M.D.
4:00 p.m.
Session III: Primary PCI Technique and Challenges
Room 104
Moscone Center
- Management of (Left and Right Ventricular) Cardiogenic Shock During Primary PCI: 2011 Approaches and Outcomes
Simon Dixon
- Hemodynamic Support During Cardiogenic Shock
William W. OaNeill
- Rationale for Left Ventricular Unloading with Impella to Reduce Infarct Size: The MINI-AMI Trial
Ajay Kirtane
FRIDAY, NOVEMBER 11
6:30 a" 8:00 a.m.
ABIOMED-SPONSORED TCT BREAKFAST SESSION a" Management of Complex Patients: Series of Case Reviews
Room 120
Moscone Center
- Building an Impella Program
- Treatment of Complex Patients Supported with Impella
Panel members / speakers:
- Theodore Schreiber, MD, Detroit Medical Center
- Roxana Mehran, MD, Mt. Sinai School of Medicine
- George Vetrovec, MD, Virginia Commonwealth University
- Faramarz Tehrani, MD, UC Davis Medical Center
- Michael Tempelhof, MD, Northwestern University
- Gopi Manthripragada, MD, University of California, Los Angeles
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
